EMCURE Emcure Pharmaceuticals Q1 FY27 results (Apr–Jun 2026) and concall
Emcure Pharmaceuticals reported a robust Q1 FY27, marked by strong revenue growth and significant profitability expansion, primarily driven by its international business and a recovering domestic market. The company completed the acquisition of Gennova, strengthening its biotech platform, and made progress on its R&D pipeline. While gross margins saw a slight compression due to mix, overall operating leverage led to improved EBITDA and PAT margins. Net debt is projected to temporarily rise in the next quarter due to M&A-related payouts.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 22.8%, net profit up 35.8% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,002 | 1,963 | 2,116 | 2,101 | 2,270 +13% | 2,363 +20% | 2,470 +17% | 2,580 +23% |
| EBITDA | 381 | 355 | 402 | 417 | 475 +25% | 493 +39% | 480 +19% | 532 +28% |
| Net profit | 202 | 156 | 197 | 215 | 251 +24% | 231 +48% | 244 +24% | 292 +36% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
